LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems
Open Access
- 1 November 2007
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 117 (11) , 3383-3392
- https://doi.org/10.1172/jci31184
Abstract
Lymphocyte activation gene-3 (LAG-3) is a cell-surface molecule with diverse biologic effects on T cell function. We recently showed that LAG-3 signaling is important in CD4+ regulatory T cell suppression of autoimmune responses. Here, we demonstrate that LAG-3 maintains tolerance to self and tumor antigens via direct effects on CD8+ T cells using 2 murine systems. Naive CD8+ T cells express low levels of LAG-3, and expression increases upon antigen stimulation. Our data show increased levels of LAG-3 protein on antigen-specific CD8+ T cells within antigen-expressing organs or tumors. In vivo antibody blockade of LAG-3 or genetic ablation of the Lag-3 gene resulted in increased accumulation and effector function of antigen-specific CD8+ T cells within organs and tumors that express their cognate antigen. Most notably, combining LAG-3 blockade with specific antitumor vaccination resulted in a significant increase in activated CD8+ T cells in the tumor and disruption of the tumor parenchyma. A major component of this effect was CD4 independent and required LAG-3 expression by CD8+ T cells. Taken together, these data demonstrate a direct role for LAG-3 on CD8+ T cells and suggest that LAG-3 blockade may be a potential cancer treatment.Keywords
This publication has 51 references indexed in Scilit:
- Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cellsBlood, 2007
- Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergyBlood, 2007
- Metalloproteases regulate T-cell proliferation and effector function via LAG-3The EMBO Journal, 2007
- Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen–specific CD8+ T-cell function in Hodgkin lymphoma patientsBlood, 2006
- Placebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone Refractory Prostate CancerJournal of Clinical Oncology, 2006
- T-cell tolerance or function is determined by combinatorial costimulatory signalsThe EMBO Journal, 2006
- Therapeutic cancer vaccinesCurrent Opinion in Immunology, 2006
- Antibody‐mediated signaling through PD‐1 costimulates T cells and enhances CD28‐dependent proliferationEuropean Journal of Immunology, 2005
- In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responsesThe Journal of Experimental Medicine, 2005
- Endothelial expression of PD‐L1 and PD‐L2 down‐regulates CD8+ T cell activation and cytolysisEuropean Journal of Immunology, 2003